In vitro characterization and pre-clinical pharmacokinetics of CP-870,893, a human anti-CD40 agonist antibody.

被引：0

作者：

Bedian, V. ^{[1
]}

Donovan, C. ^{[1
]}

Gardner, J. ^{[1
]}

Natoli, E. ^{[1
]}

Paradis, T. ^{[1
]}

Alpert, R. ^{[1
]}

Wang, H. ^{[1
]}

Shepard, R. ^{[1
]}

Wentland, J. ^{[1
]}

Gladue, R. ^{[1
]}

机构：

[1] Pfizer Global Res & Dev, Groton, CT USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：109S / 109S

页数：1

共 48 条

[21] Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates
Kelley, Sean K.
Gelzleichter, Thomas
Xie, Dong
Lee, Wyne P.
Darbonne, Walter C.
Qureshi, Ferhan
Kissler, Kim
Oflazoglu, Ezogelin
Grewal, Iqbal S.
BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (08) : 1116 - 1123
[22] ANTI-CD40 ANTIBODY-BINDING MODULATES HUMAN MULTIPLE-MYELOMA CLONOGENICITY IN-VITRO
TONG, AW
ZHANG, BQ
MUES, G
SOLANO, M
HANSON, T
STONE, MJ
BLOOD, 1994, 84 (09) : 3026 - 3033
[23] ANTI-CD40 ANTIBODY-BINDING MODULATES HUMAN MULTIPLE-MYELOMA CLONOGENICITY IN-VITRO
TONG, AW
SU, D
MUES, G
SOLANO, M
STONE, MJ
BLOOD, 1994, 84 (10) : A170 - A170
[24] Pre-clinical results in pig-to-non-human primate islet xenotransplantation using anti-CD40 antibody (2C10R4)-based immunosuppression
Shin, Jun-Seop
Kim, Jong-Min
Min, Byoung-Hoon
Yoon, Il Hee
Kim, Hyun Je
Kim, Jung-Sik
Kim, Yong-Hee
Kang, Seong-Jun
Kim, Jiyeon
Kang, Hee-Jung
Lim, Dong-Gyun
Hwang, Eung-Soo
Ha, Jongwon
Kim, Sang-Joon
Park, Wan Beom
Park, Chung-Gyu
XENOTRANSPLANTATION, 2018, 25 (01)
[25] Pharmacokinetics and Pharmacodynamics of ASKP1240, a Fully Human Anti-CD40 Antibody, in Normal and Renal Transplanted Cynomolgus Monkeys
Ma, Anlun
Dun, Hao
Song, Lijun
Hu, Yanxin
Zeng, Lin
Bai, Jieying
Zhang, Guangzhou
Kinugasa, Fumitaka
Miyao, Yasuhiro
Sakuma, Shozo
Okimura, Kazumichi
Kasai, Noriyuki
Daloze, Pierre
Chen, Huifang
TRANSPLANTATION, 2014, 97 (04) : 397 - 404
[26] Comparative efficacy of rituximab and a fully human anti-CD40 antagonist antibody in in vitro and in xenograft lymphoma models.
Long, L
Tong, X
Patawaran, M
Luqman, M
BLOOD, 2003, 102 (11) : 646A - 646A
[27] B Cell Depletion Is Not Required for Prolongation of Renal Allograft Survival in Non-Human Primates Using a Novel Anti-CD40 Blocking Antibody.
Rush, J.
Cordoba, F.
Wieczorek, G.
Audet, M.
Schneider, M.
Patel, D.
Heusser, C.
Bruns, C.
Ulrich, P.
Slade, A.
Klupp, J.
TRANSPLANTATION, 2014, 98 : 379 - 380
[28] Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody
Ristov, Jacinda
Espie, Pascal
Ulrich, Peter
Sickert, Denise
Flandre, Thierry
Dimitrova, Mirela
Mueller-Ristig, Dorothee
Weider, Doris
Robert, Gautier
Schmutz, Patrick
Greutmann, Barbara
Cordoba-Castro, Francisco
Schneider, Martin A.
Warncke, Max
Kolbinger, Frank
Cote, Serge
Heusser, Christoph
Bruns, Christian
Rush, James S.
AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 (12) : 2895 - 2904
[29] Pre-clinical results in pig-to-nonhuman primate islet xenotransplantation using anti-CD40 antibody 2C10R4)-based immunosuppression
Shin, Jun-Seop
Kim, Jong-Min
Min, Byoung-Hoon
Yoon, Il-Hee
Kim, Jung-Sik
Kang, Seong-Jun
Ha, Jongwon
Kim, Sang-Joon
Park, Chung-Gyu
XENOTRANSPLANTATION, 2017, 24 (05)
[30] Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: Clinical implications
Tai, YT
Catley, LP
Mitsiades, CS
Burger, R
Podar, K
Shringpaure, R
Hideshima, T
Chauhan, D
Hamasaki, M
Ishitsuka, K
Richardson, P
Treon, SP
Munshi, NC
Anderson, KC
CANCER RESEARCH, 2004, 64 (08) : 2846 - 2852

← 1 2 3 4 5 →